OncoMatch/Clinical Trials/NCT06959615
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Is NCT06959615 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including JAB-23E73 and JAB-23E73 for advanced solid tumor.
Treatment: JAB-23E73 · JAB-23E73 — This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS gene mutation
evidence of KRAS gene alteration (including gene mutation and wild type amplification)
Required: KRAS amplification
evidence of KRAS gene alteration (including gene mutation and wild type amplification)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: RAS targeting agent
Previous treatment with rat sarcoma (RAS) targeting agents
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Impaired cardiovascular function or clinically significant cardiac disease; QTcF >470 msec excluded
Adequate organ function. Impaired cardiovascular function or clinically significant cardiac disease. Mean QT interval corrected using Fridericia's formula (QTcF) >470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06959615 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RAS targeting agent disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS gene mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS amplification is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify